Supplements
Download PDF
Jonathan Kaufman, MD
Beth Faiman, RN, MSN, APRN, BC, AOCN
Stephanie S. Minich, PharmD, BCOP
James O. Armitage, MD

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: September 30th, 2009 - September 30th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for pharmacists involved in the treatment and management of patients with MM.

Learning Objectives
At the completion of this activity participants should be able to:

  • Identify new therapeutic options for the treatment of patients with MM
  • Describe strategies for the retreatment of relapsed MM patients
  • Discuss role(s) the oncology pharmacist has in the overall management of the MM patient


Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:



Name of Planner
or Manager
Company Reported Financial
Relationship
Nancy Nesser, PharmD, JD MLI Nothing to disclose
Elizabeth Cohen COEXM Nothing to disclose



Faculty Disclosures
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.

Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.

Stephanie Taber, PharmD, BCOP has nothing to disclose.

James O. Armitage, MD is a consultant for Allos, Eisai, Seattle Genetics, and Ziopharm.

*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.

Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Cases in Multiple Myeloma: The Role of Oncology Pharmacists on an Interprofessional Team to Improve Patient Care and Outcomes
Stephanie S. Minich, PharmD, BCOP
Supplements published on August 29, 2011
Conference Faculty Perspectives: Highlights From ASCO 2010
Paul Richardson, MD, William Bensinger, MD, Kenneth C. Anderson, MD, Melissa Alsina, MD, Jonathan Kaufman, MD
Supplements published on August 13, 2010
Health System/Regional Variations in the Delivery of Care for Multiple Myeloma
Gary M. Owens, MD, Jatin Shah, MD, Rusty Crawford, RPh, BCOP, Sin (Masha) Lam, PharmD, BCOP, Stephanie S. Minich, PharmD, BCOP
Supplements published on March 30, 2010
Considerations in Multiple Myeloma: Case Studies in Front-line Therapy
Katherine Sanvidge Shah, PharmD, BCOP, Jonathan Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Nicole Wilson, PharmD, BCOP
Supplements published on February 17, 2010
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Considerations in Multiple Myeloma: Maintenance Therapy
Sagar Lonial, MD, Elizabeth Bilotti, MSN, APRN, BC, OCN®, Jonathan Kaufman, MD, Timothy McGuire, PharmD, FCCP, BCOP
Supplements published on May 11, 2009
Considerations in Multiple Myeloma: Renal Dysfunction
Sagar Lonial, MD, Beth Chen, PharmD, BCOP, Beth Faiman, RN, MSN, APRN, BC, AOCN, Jonathan Kaufman, MD
Supplements published on May 7, 2008
Last modified: March 24, 2014